Future therapies for the myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 22-27

  Scherber, Robyn ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Essential thrombocythemia; Jak2 inhibitors; Myelofibrosis; Myeloproliferative neoplasm; Polycythemia vera; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTIFIBROTIC AGENT; AZD 1480; CYT 387; EVEROLIMUS; HISTONE DEACETYLASE INHIBITOR; HYDROXYUREA; IMMUNOMODULATING AGENT; INCB 018424; INTERFERON; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; LY 2784544; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANOBINOSTAT; PEGINTERFERON ALPHA2A; PHENYLALANINE; POMALIDOMIDE; PROTEIN TYROSINE KINASE; SB 1518; TG 101348; UNCLASSIFIED DRUG; VALINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG INHIBITION; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 79551479092     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0068-4     Document Type: Article

References (33)

1. JW Vardiman J Thiele DA Arber RD Brunning MJ Borowitz A Porwit, et al. 2009 The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood 114 5 937 951 1:CAS:528:DC%2BD1MXps1eit70%3D 10.1182/blood-2009-03-209262 19357394 This key reference addresses the WHO changes in the diagnosis of the MPNs, addressing the neoplastic nature of the illnesses and the current diagnostic criteria
2. RA Mesa S Verstovsek F Cervantes, et al. 2007 Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Leuk Res 31 6 737 740 10.1016/j.leukres.2006.12.002 17210175 (Pubitemid 46855906)
3. RA Mesa 2008 New insights into the pathogenesis and treatment of chronic myeloproliferative disorders Curr Opin Hematol 15 2 121 126 1:CAS:528: DC%2BD1cXjslWitrc%3D 10.1097/MOH.0b013e3282f3debd 18300758 (Pubitemid 351323152)
4. F Cervantes B Dupriez A Pereira, et al. 2009 New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 13 2895 2901 1:CAS:528:DC%2BD1MXktFWnsLc%3D 10.1182/blood-2008-07-170449 18988864 This article presents the most comprehensive prognostic criteria for myelofibrosis ever published, based on high-quality analysis of over 1,000 patients
5. RA Mesa J Niblack M Wadleigh, et al. 2007 The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients Cancer 109 1 68 76 10.1002/cncr.22365 17123268 (Pubitemid 46120195)
6. R Landolfi L Di Gennaro T Barbui V De Stefano G Finazzi R Marfisi, et al. 2007 Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera Blood 109 6 2446 2452 1:CAS:528:DC%2BD2sXnslygsL0%3D 10.1182/blood-2006-08-042515 17105814 (Pubitemid 46425887)
7. R Landolfi R Marchioli J Kutti H Gisslinger G Tognoni C Patrono, et al. 2004 Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2 114 124 1:CAS:528:DC%2BD2cXjs1aluw%3D%3D 10.1056/NEJMoa035572 14711910 (Pubitemid 38056222)
8. G Finazzi T Barbui 2005 Risk-adapted therapy in essential thrombocythemia and polycythemia vera Blood Rev 19 5 243 252 10.1016/j.blre.2005.01.001 15963833 (Pubitemid 40814453)
9. AM Vannucchi E Antonioli P Guglielmelli G Longo A Pancrazzi V Ponziani, et al. 2007 Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden Leukemia 21 9 1952 1959 1:CAS:528: DC%2BD2sXptlSrsb0%3D 10.1038/sj.leu.2404854 17625606 (Pubitemid 47299969)
10. CN Harrison PJ Campbell G Buck K Wheatley CL East D Bareford, et al. 2005 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia N Engl J Med 353 1 33 45 1:CAS:528:DC%2BD2MXmtVWjsbs%3D 10.1056/NEJMoa043800 16000354 (Pubitemid 41007805)
11. JJ Kiladjian B Cassinat S Chevret P Turlure N Cambier M Roussel, et al. 2008 Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera Blood 112 8 3065 3072 1:CAS:528:DC%2BD1cXht1OmtbfE 10.1182/blood-2008-03-143537 18650451 This is the first report of molecular remission in patients with PV with the use of interferon
12. Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, Cortes J, Richie MA, Borthakur G, et al.: Pegylated Interferon-ALFA-2A (PEG-IFN-α-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV) [abstract]. ASH Annual Meeting Abstracts 2008, 112(11):658.
13. RA Mesa 2009 How I treat symptomatic splenomegaly in patients with myelofibrosis Blood 113 22 5394 5400 1:CAS:528:DC%2BD1MXntVertLg%3D 10.1182/blood-2009-02-195974 19332765
14. J Huang A Tefferi 2009 Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level Eur J Haematol 83 2 154 155 1:CAS:528:DC%2BD1MXpvFehsLo%3D 10.1111/j.1600-0609.2009.01266.x 19366369
15. F Cervantes JC Hernandez-Boluda A Alvarez E Nadal E Montserrat 2000 Danazol treatment of idiopathic myelofibrosis with severe anemia Haematologica 85 6 595 599 1:CAS:528:DC%2BD3cXmsVGgsrc%3D 10870115
16. RA Mesa DP Steensma A Pardanani CY Li M Elliott SH Kaufmann, et al. 2003 A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia Blood 101 7 2534 2541 1:CAS:528:DC%2BD3sXivVWgur4%3D 10.1182/blood-2002-09-2928 12517815 (Pubitemid 36857609)
17. A Tefferi RA Mesa DM Nagorney G Schroeder MN Silverstein 2000 Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients Blood 95 7 2226 2233 1:CAS:528:DC%2BD3cXitFeitr4%3D 10733489
18. MA Elliott MG Chen MN Silverstein A Tefferi 1998 Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia British Journal of Haematology. 103 2 505 511 1:STN:280:DyaK1M%2FktlKhug%3D%3D 10.1046/j.1365-2141.1998.00998.x 9827926 (Pubitemid 28522460)
19. A Tefferi J Cortes S Verstovsek RA Mesa D Thomas TL Lasho, et al. 2006 Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood 108 4 1158 1164 1:CAS:528:DC%2BD28Xot1ymtL0%3D 10.1182/blood-2006-02-004572 16609064 (Pubitemid 44232010)
20. LN Faoro A Tefferi RA Mesa 2005 Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia Eur J Haematol 74 2 117 120 1:CAS:528:DC%2BD2MXitVGnsL0%3D 10.1111/j.1600-0609.2004. 00370.x 15654901 (Pubitemid 40175314)
21. N Kroger E Holler G Kobbe M Bornhauser R Schwerdtfeger H Baurmann, et al. 2009 Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Blood 114 26 5264 5270 10.1182/blood-2009-07-234880 19812383 This is the most comprehensive prospective trial of allogeneic stem cell transplantation in myelofibrosis
22. S Verstovsek H Kantarjian RA Mesa AD Pardanani J Cortes-Franco DA Thomas, et al. 2010 Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis N Engl J Med 363 12 1117 1127 1:CAS:528:DC%2BC3cXhtFOltrjJ 10.1056/NEJMoa1002028 20843246 This is the first major report of the efficacy of a JAK2 inhibitor in patients with myelofibrosis
23. RA Mesa S Verstovsek HM Kantarjian AD Pardanani S Friedman R Newton, et al. 2008 INCB018424, a Selective JAK1/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF) Blood 112 11 1760
24. RA Mesa H Kantarjian A Tefferi, et al. 2009 Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial [abstract] Blood 114 22 a3917
25. AD Pardanani R Jason M Gotlib M Catriona Jamieson M Jorge Cortes M Moshe Talpaz M Richard Stone, et al. 2009 A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden [abstract] Blood 114 22 a755
26. S Verstovsek O Odenike B Scott, et al. 2009 Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/Polycythemia Vera Myelofibrosis [abstract] Blood 114 22 a3905
27. E Hexner JD Goldberg JT Prchal, et al. 2009 A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract] Blood 114 22 a754
28. RA Mesa AD Pardanani K Hussein W Wu S Schwager MR Litzow, et al. 2010 Phase1/-2 study of pomalidomide in myelofibrosis Am J Hematol 85 2 129 130 1:CAS:528:DC%2BC3cXitlKmsrg%3D 20052748
29. J Mascarenhas X Wang A Rodriguez, et al. 2009 A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) [abstract] Blood 114 22 a308
30. AM Vannucchi P Guglielmelli E Gattoni, et al. 2009 RAD001, an inhibitor of mTOR, shows clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (PPV/PET MF) [abstract] Blood 114 22 a307
31. S Verstovsek F Passamonti A Rambaldi, et al. 2009 A phase 2 study of INCB018424, an oral, selective JAK1/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea [abstract] Blood 114 22 a311 First report of a JAK2 inhibitor in patients with ET and PV
32. AR Moliterno E Hexner GJ Roboz, et al. 2009 An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract] Blood 114 22 a753
33. A Quintas-Cardama H Kantarjian T Manshouri R Luthra Z Estrov S Pierce, et al. 2009 Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera J Clin Oncol 27 32 5418 5424 1:CAS:528:DC%2BD1MXhsFKkt7vP 10.1200/JCO.2009.23.6075 19826111